The future of the global rubella vaccine market looks promising with opportunities in the hospital, NGO, and pediatric clinic markets. The global rubella vaccine market is expected to reach an estimated $245 million by 2030 with a CAGR of 4.1% from 2024 to 2030. The major drivers for this market are growing demand for combination vaccines and rising adoption of rubella vaccination programs in developing countries.
Some of the key questions
answered in this exclusive report are:
Q.1. What are some of
the most promising, high-growth opportunities for the rubella vaccine market by
type (monovalent formulation, measles-rubella vaccine, measles, mumps, rubella
vaccine, and measles mumps rubella varicella vaccine), end use (hospitals,
NGO’s, pediatric clinics, and others), and region (North America, Europe, Asia
Pacific, and the Rest of the World)?
Q.2. Which segments will
grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and
why?
Q.4. What are the key
factors affecting market dynamics? What are the key challenges and business
risks in this market?
Q.5. What are the
business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market
and the reasons behind them?
Q.7. What are some of
the changing demands of customers in the market?
Q.8. What are the new
developments in the market? Which companies are leading these developments?
Q.9. Who are the major
players in this market? What strategic initiatives are key players pursuing for
business growth?
Q.10. What are some of
the competing products in this market and how big of a threat do they pose for
loss of market share by material or product substitution?
Q.11. What M&A activity
has occurred in the last 5 years and what has its impact been on the industry?
Market Segmentation:
In this market,
monovalent formulation, measles-rubella vaccine, measles, mumps, rubella
vaccine, and measles mumps rubella varicella vaccine are the major segments of
rubella vaccine market by application type. Lucintel forecasts that
measles-rubella vaccine is expected to witness highest growth over the forecast
period due to it growing usage to protect against two highly contagious
diseases including measles and rubella.
Within this market,
pediatric clinic is expected to witness highest growth over the forecast period
due to growing preference for this setting among children to get vaccinated
against rubella.
North America is
expected to witness highest growth over the forecast period due to high
vaccination coverage rates and presence of key manufacturer in the region.
Johnson & Johnson,
Sanofi Pasteur, Bavarian Nordic, Medimmune, China National Biotec,
Glaxosmithkline, and Pfizer are the major suppliers in the rubella vaccine
market.
About
Lucintel
Lucintel, the premier global
management consulting and market research firm, creates winning strategies for
growth. It offers market assessments, competitive analysis, opportunity
analysis, growth
consulting, M&A, and due diligence services to executives and
key decision-makers in a variety of industries.
Contact:
Roy Almaguer
Lucintel
Dallas, Texas, USA
Email: roy.almaguer@lucintel.com
Tel. 972.636.5056
Related Reports
1. Pharmaceutical Contract Manufacturing Market
3. Stent Market
5. 3D
Printing Medical Device Market
8. Medical Lifting Sling
Market
10. Stretcher Market
No comments:
Post a Comment